Skip to main content

Advertisement

SpringerLink
Log in

Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Patients with depression can be mistakenly labeled as treatment-resistant if they fail to receive an adequate first-line antidepressant trial. Adding second-line agents to the treatment regimens can create an additional burden on both the patients and the healthcare system. Objectives To determine if depressed patients receive an adequate antidepressant trial prior to starting second-line therapy and to investigate the association between the type of second-line treatment and severity of illness or depression among unipolar versus bipolar patients. Setting Oklahoma Medicaid claims data between 2006 and 2011. Methods Subjects were depression-diagnosed adult patients with at least two prescriptions of antidepressants followed by a second-line agent. Patients were categorized into one of three groups: an atypical antipsychotic, other augmentation agents (lithium, buspirone, and triiodothyronine), or adding antidepressants, based on the type of second-line therapy. An adequate trial was defined per the American Psychiatric Association guidelines. Factors associated with the type of treatment were tested using multinomial logistic regression models stratified by type of depression (unipolar vs. bipolar patients). Main outcome measure Variables used to measure receiving an adequate antidepressant trial included: trial duration, adherence, dose adequacy, and number of distinct antidepressant trials. Results A total of 3910 patients were included in the analysis. Most subjects reached the recommended antidepressant dose. However, 28 % of patients had an antidepressant trial duration <4 weeks and only 60 % tried at least two antidepressant regimens prior to adding second-line therapy. Approximately 50 % of the subjects were non-adherent across all groups. Severity of illness and receipt of an adequate antidepressant trial were not predictors of the type of second-line treatment. Conclusion Many patients do not receive an adequate antidepressant trial before starting a second-line agent. The type of second-line treatment was independent of severity of depression. These findings support policies that require reviewing the recommended dose and duration of the first-line antidepressant before adding second-line agents. Healthcare providers need to review the patient’s history and reconsider the evidence for prescribing second-line agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–105.

    Article  PubMed  Google Scholar 

  2. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–59.

    Article  PubMed  Google Scholar 

  3. American Psychiatric Association (Internet). Practice guidelines for the treatment of patients with major depressive disorder (cited 2015, July 8). http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf (2010).

  4. Nelson JC. The STAR*D study: a four-course meal that leaves us wanting more. Am J Psychiatry. 2006;163(11):1864–6.

    Article  PubMed  Google Scholar 

  5. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry. 1990;51(Suppl):39–47 (discussion 48–50).

    PubMed  Google Scholar 

  6. Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24(2):131–61.

    Article  CAS  PubMed  Google Scholar 

  7. National Guideline Clearinghouse (Internet). Diagnosis and treatment of depression in adults: 2012 clinical practice guidelines (cited 2015, Oct 9). http://www.guideline.gov/content.aspx?id=39432 (2012).

  8. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):18–25.

    CAS  PubMed  Google Scholar 

  9. Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, et al. Discontinuation of use and switching of antidepressants: influence of patient–physician communication. JAMA. 2002;288(11):1403–9.

    Article  PubMed  Google Scholar 

  10. Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr. 2007;12(8 Suppl 13):1–27.

    PubMed  Google Scholar 

  11. Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs. 2008;22(11):963–73.

    Article  PubMed  Google Scholar 

  12. Givens JL, Datto CJ, Ruckdeschel K, Knott K, Zubritsky C, Oslin DW, et al. Older patients’ aversion to antidepressants. A qualitative study. J Gen Intern Med. 2006;21(2):146–51.

    PubMed  PubMed Central  Google Scholar 

  13. Hunot VM, Horne R, Leese MN, Churchill RC. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry. 2007;9(2):91–9.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–10.

    Article  PubMed  Google Scholar 

  15. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565–74 (discussion 575–567).

    Article  PubMed  Google Scholar 

  16. Liu X, Tepper PG, Able SL. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder. Int Clin Psychopharmacol. 2011;26(3):173–80.

    Article  CAS  PubMed  Google Scholar 

  17. Wu CH, Farley JF, Gaynes BN. The association between antidepressant dosage titration and medication adherence among patients with depression. Depress Anxiety. 2012;29(6):506–14.

    Article  PubMed  Google Scholar 

  18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

    Article  CAS  PubMed  Google Scholar 

  19. Gibson TB, Jing Y, Smith Carls G, Kim E, Bagalman JE, Burton WN, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16(5):370–7.

    PubMed  Google Scholar 

  20. Petersen T, Papakostas GI, Posternak MA, KantA GuykerWM, Iosifescu DV, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25(4):336–41.

    Article  PubMed  Google Scholar 

  21. Correa R, Akiskal H, Gilmer W, Nierenberg AA, Trivedi M, Zisook S. Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? J Affect Disord. 2010;127(1–3):10–8.

    Article  CAS  PubMed  Google Scholar 

  22. Vazquez G, Tondo L, Baldessarini RJ. Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: a meta-analytic review. Pharmacopsychiatry. 2011;44(1):21–6.

    CAS  PubMed  Google Scholar 

  23. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63(11):963–71.

    Article  PubMed  Google Scholar 

  24. Russell JM, Hawkins K, Ozminkowski RJ, Orsini L, Crown W, Kennedy S, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65(3):341–7.

    Article  PubMed  Google Scholar 

  25. Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22(6):363–73.

    Article  PubMed  Google Scholar 

  26. Jing Y, Kalsekar I, Curkendall SM, Carls GS, Bagalman E, Forbes RA, et al. Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression. Clin Ther. 2011;33(9):1246–57.

    Article  PubMed  Google Scholar 

  27. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA. 2002;287(2):203–9.

    Article  PubMed  Google Scholar 

  28. Fullerton CA, Busch AB, Normand SL, McGuire TG, Epstein AM. Ten-year trends in quality of care and spending for depression: 1996 through 2005. Arch Gen Psychiatry. 2011;68(12):1218–26.

    Article  PubMed  Google Scholar 

  29. Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7(1):58–62.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funding was requested or received in conjunction with this project. Oklahoma Medicaid data was provided by the Oklahoma Healthcare Authority, under a contract with the University of Oklahoma College of Pharmacy.

Conflicts of interest

The authors report no actual or possible conflicts of interest, including financial, personal or other relationships with other individuals or organizations that might inappropriately influence or could be perceived to influence their work.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical, Social and Administrative Sciences, School of Pharmacy, D’Youville College, Buffalo, NY, 14201, USA

    Amany K. Hassan

  2. Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, Oklahoma City, OK, 73117, USA

    Kevin C. Farmer

  3. Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, Tulsa, OK, 74135-2512, USA

    Nancy C. Brahm

  4. Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma, Oklahoma City, OK, 73117, USA

    Barbara R. Neas

Authors
  1. Amany K. Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin C. Farmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nancy C. Brahm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbara R. Neas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amany K. Hassan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hassan, A.K., Farmer, K.C., Brahm, N.C. et al. Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression. Int J Clin Pharm 38, 429–437 (2016). https://doi.org/10.1007/s11096-016-0272-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-016-0272-y

Keywords

Search

Navigation